TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05454553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myocardial perfusion SPECT
Description: For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)
Study: NCT06344624

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT group
Description: Brief cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Laughter group
Description: Laughter yoga therapy
Study: NCT05606562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental care
Description: Participants will be offered free dental care
Study: NCT05599295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Description: Oritavancin for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Description: Oritavancin for IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oritavancin
Description: Oritavancin for IV infusion
Study: NCT05843279

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Myofunctional therapy
Description: In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy
Description: In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.
Study: NCT04195776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Douche
Description: 660 mg TFV in 125 mL hypo-osmolar solution
Study: NCT06363266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEMPO
Description: Stage 1 interventions (week 1-12): After 12 weeks, response will be determined. At recruitment, at least one member of the dyad must report anxiety symptoms defined as a Hospital Anxiety and Depression Scale (HADS)-Anxiety subscale score \> 6. After Stage 1, for the dyad to be TEMPO Responder, both members' anxiety scores on the HADS-Anxiety must be \< 6 or decreased by at least 2 points. If both members of the dyad had anxiety symptoms at recruitment, then both must meet a response criterion. As soon as one dyad member does not meet the response criterion, the dyad is TEMPO non-responder.~Stage 2 interventions (week 14-25): TEMPO responders continue with TEMPO. Non-responders will be re-randomized to: a) more time with TEMPO or b) add non-health care professional guidance (8 x 20-minute telephone calls). Guides' training will include TEMPO review, their role and the manual. Semi-structured exit interview will gather guides' experiences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Monitoring dyads' anxiety
Description: Stage 1 interventions (week 1-12): Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices).~Stage 2 interventions (week 14-25): Dyads not responding to active monitoring will be stepped up to TEMPO; responders to active monitoring will only be invited to complete the follow-up measures.
Study: NCT06327022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social media-based electronic bibliotherapy
Description: Eight weekly sessions of bibliotherapy are delivered via their daily social media.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The routine services provided by community centers
Study: NCT06401629

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NPRP criteria
Description: Under the NPRP criterion, the plasma glucose level at each time point (TP1, TP2, and TP3) is multiplied by its weight (Doi et al. 2022), and the sum of these products yields the unified Doi's Weighted Average Glucose (dwAG) value for each woman. The dwAG is then categorized into four groups: a dwAG of 6.8 or lower, \>6.8 to ≤7.5, \>7.5 to ≤8.6, and above 8.6 mmol/L, indicating normal gestational glycemia (NGG), impaired gestational glycemia (IGG), gestational diabetes mellitus (GDM), and high-risk gestational diabetes mellitus (hGDM), respectively (Doi et al. 2022).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IADPSG criteria
Description: The IADPSG criteria define GDM as any one of the three-time points above specific thresholds: the time point prior to glucose ingestion (TP1) is considered abnormal when the fasting plasma glucose (FPG) value is ≥ 5.1 mmol/L, the 1-hour time-point after glucose ingestion (TP2) is considered abnormal when the value is ≥ 10 mmol/L, and the 2-hour time-point after glucose ingestion (TP3) is considered abnormal when the Post-Load Plasma Glucose levels are ≥ 8.5 mmol/L (Metzger et al. 2010). Put simply, meeting any one of these cut-offs results in a GDM diagnosis, regardless of whether the other time points show normal values or not (Metzger et al. 2010).
Study: NCT05662618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous selective arteriography of peripheral arteries
Description: Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous selective arteriography of peripheral arteries
Description: Paclitaxel coated balloon catheter for the treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery.
Study: NCT05229497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days
Study: NCT05466643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 0.3mg
Description: 1 tablet, Orally, Once daily single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP16001 Placebo
Description: 1 tablet, Orally, Once daily single dose
Study: NCT06296563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: FOLFOX-hepatic artery infusion for 2 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg, po, qd,q3w,up to one year of use at most.
Study: NCT05229497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV infusion,Specified dose on specified days
Study: NCT05179343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active AffeX-CT device
Description: (Trans-cutaneous Autonomic Neurostimulation) tAN treatment will be administered using AffeX-CT device (a device based on a totally TENS unit). AffeX device comprises of a battery-operated control unit, two electrode pairs arranged on ear clips and connected to the control unit with electrical leads. The AffeX device generates an electrical signal that is used to stimulate the nerves that naturally control the output from the sympathetic nervous system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham AffeX-CT device
Description: Sham Totally TENS device. The device is identical to the active device used in the study, but its only purpose is to act as a placebo. The ear-clip electrodes have been modified so that the electric current is not transmitted to the participant.
Study: NCT06149247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericin
Description: HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechlorethamine Topical Gel
Description: Valchlor is an FDA-approved drug for the treatment of CTCL.
Study: NCT06290440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telepharmacy-led counselling
Description: The counselling process will be delivered as follows: (1) researchers assist patients in signing up and using the telepharmacy application; (2) researchers send the counselling information from the telepharmacy application to the patient's account (the information will be provided as leaflets and 3-5-minute videos to improve the accessibility); (3) the integrated chatbot system forwards any additional questions or concerns of the patients to the counselling pharmacists; and (4) the pharmacists directly address the patient's questions or concerns through phone calls within the shortest possible timeframe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led counselling
Description: Pharmacists will counsel the patients on how to use their OAC. Each counselling section will take approximately 7-15 minutes, depending on the patient's questions or concerns. The counselling contents have already been compiled and validated by NDGD Hospital to ensure rationale and simplicity for every patient. Counselling pharmacists have received specialised training in drug information and patient communication so intervention delivery will be consistent across different pharmacists.
Study: NCT06055166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
Description: Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
Description: Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
Description: Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
Description: Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
Study: NCT04075435

Intervention type: DRUG
Group type: OTHER
Intervention: high CBD/low THC sublingual solution
Description: Hemp derived solution to be administered sublingually twice daily.
Study: NCT06381830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Participants will undergo two separate apheresis procedures, including: G-CSF primed hematopoietic stem cell collection and peripheral blood mononuclear cell apheresis for CAR-T cell manufacturing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Participants are designed to receive myeloablative conditioning regimen prior to infusion of a minimum 2 x 10\^6 CD34+ stem cells/kilogram.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T Cell Therapy
Description: CAR-T cells will be infused within 7 days after autologous hematopoietic stem cell infusion (2-10×10\^6 CAR-T/kg，ivgtt).
Study: NCT06127329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BAI combine with DEB-BACE
Description: 1. First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 \~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 \~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery.
Study: NCT05728814

Intervention type: DRUG
Intervention: Dostarlimab
Description: The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles.
Study: NCT05808036

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention: DOMINO app
Description: Life style intervention and diet low in FODMAPs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention: DOMINO app
Description: Life style intervention and diet low in FODMAPs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention: low FODMAP diet
Description: Strict low FODMAP diet.
Study: NCT04818515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Oral; Tablet
Study: NCT04793399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 MG Monotherapy
Description: One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
Description: 12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
Study: NCT06412692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Motivational Interviewing Technique
Description: Motivational interviewing technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life of adolesce.
Study: NCT05077696

Intervention type: OTHER
Intervention: Drawing a tube of blood (serum)
Description: dosage of neurofilaments and comparison with a final diagnosis one year after sampling.
Study: NCT05899855

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01352663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wockhardt's Insulin Analogue (Recomb)
Description: Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
Study: NCT06430437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: Drug: SHR-A1811 administered intravenously every 3 weeks (Q3W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Description: Drug: Camrelizumab administered intravenously every 3 weeks (Q3W)~Drug: Pemetrexed Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Paclitaxel Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Carboplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Cisplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)
Study: NCT05151588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Chemoradiation as either radical treatment or post-operative treatment after surgery
Study: NCT06327243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic tape ( kinesio tape)
Description: This group will receive the tape on their quadriceps femoris muscle. First, the tape will be cut in a Y-shaped Kinesio type and then applied over the quadriceps femoris muscle. The tape will be applied at a point of 5 cm inferior to the anterior superior iliac spine to the patella (origin to insertion), with the patient in a supine position with 25% tension on the tape. Then, each patient will flex his or her knee, and the Y-shaped tape (the end of the tape) will be circled around the patella, ending at its inferior side with no tension.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Taping
Description: Sham taping will be applied horizontally across the muscle fibers without any stretching. the tape here will be applied transverse to the quadriceps femoris muscle. The patients will be in a supine position with their hips flexed at 30 degrees and their knees flexed at 60 degrees.
Study: NCT05641064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5mcg/kg/h
Description: Continuous infusion of dexmedetomidine in 0.5mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 mcg/kg/h
Description: Continuous infusion of dexmedetomidine in 1mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
Study: NCT05070780

Intervention type: DEVICE
Intervention: Robot-assisted examination
Description: evaluation of muscle tone with Robot-assisted perturbation

Intervention type: DEVICE
Intervention: Robot-assisted examination
Description: evaluation of muscle tone with Robot-assisted perturbation

Intervention type: DEVICE
Intervention: Robot-assisted examination
Description: evaluation of muscle tone with Robot-assisted perturbation
Study: NCT06180512

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine high dose
Description: 4 intakes of 5 g of beta alanine every 1 hour and 15 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine low dose
Description: 4 intakes of 2.5 g of beta alanine every 1 hour and 15 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 4 intakes of 2.5 g of wheat semolina every 1 hour and 15 minutes.
Study: NCT05901922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills training
Description: In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
Study: NCT05995392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical spironolactone ophthalmic solution, 0.005 mg/cc
Description: Used four times a day in both eyes for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Used four times a day in both eyes for 4 weeks.
Study: NCT05309941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal Cues Nutrition Messaging
Description: Participants will view a 5 minute nutrition education video focused on intuitive eating principles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External Cues Nutrition Messaging
Description: Participants will view a 5 minute nutrition education video focused on traditional nutrition education principles such as label reading.